Anti-PCSK9 Antibody Formulation for Stability and Low Viscosity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic antibodies, such as those targeting PCSK9, face challenges in maintaining stability during storage and administration due to degradation, aggregation, and undesired chemical modifications in liquid formulations, necessitating improved pharmaceutical formulations.
Innovation Solution
A liquid pharmaceutical formulation comprising a human antibody that binds to PCSK9, buffered with histidine, containing an organic cosolvent like polysorbate 20, a stabilizer like sucrose, and optionally a viscosity reducer like arginine hydrochloride, with specific concentration and pH ranges to maintain stability and suitable viscosity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If therapeutic antibodies are formulated in liquid solution to enable administration, then the antibody becomes suitable for patient administration, but the antibody is prone to degradation, aggregation, or undesired chemical modifications
Solution Approach 1:
The patent introduces specific excipients as intermediary substances that mediate between the antibody and the formulation environment. These include: (1) Buffers (e.g., histidine, arginine) that mediate pH control and chemical stability; (2) Surfactants (e.g., polysorbate 20, poloxamer 188) that mediate aggregation prevention; (3) Sugars (e.g., sucrose, trehalose) that mediate stabilizing the antibody structure. These intermediary excipients enable liquid formulation suitable for administration while protecting the antibody from degradation and aggregation.
Solution Approach 2:
The patent systematically optimizes formulation parameters including pH (adjusted via buffers to specific ranges), concentration levels of excipients, temperature conditions, and excipient ratios. By controlling these parameters within specific ranges, the formulation maintains antibody stability while remaining suitable for administration. For example, pH is controlled within specific ranges using buffer systems, and excipient concentrations are optimized to prevent aggregation while maintaining solubility.
2Quantity of substance
If the antibody concentration is increased to improve therapeutic efficacy, then the treatment effectiveness is enhanced, but the formulation viscosity increases and stability decreases
Solution Approach 1:
The patent uses excipients that create a protective environment around the antibody molecules, effectively copying the stabilizing function that would otherwise require lower concentrations. The excipients (surfactants, buffers, sugars) create a molecular shield that allows higher antibody concentrations without proportionally increasing aggregation or degradation, thus maintaining stability while enhancing therapeutic efficacy.
Solution Approach 2:
The patent creates a composite formulation system combining the antibody with multiple excipients in specific ratios. This composite approach allows the formulation to achieve both high antibody concentration for therapeutic efficacy and maintained stability through the synergistic effects of multiple excipients working together to prevent aggregation and degradation at elevated concentrations.
3Stability of the object's composition
If excipients are added to improve antibody stability, then the antibody remains stable during storage, but the formulation complexity and manufacturing difficulty increase
Solution Approach 1:
The patent segments the formulation into distinct functional components, each with specific roles: (1) Buffer system for pH control and chemical stability; (2) Surfactant component for aggregation prevention; (3) Sugar component for structural stabilization. This segmentation allows each excipient class to be optimized independently and simplifies the formulation development process by assigning specific functions to specific components, reducing overall formulation complexity.
Solution Approach 2:
The patent identifies excipients that perform multiple functions simultaneously. For example, buffers not only control pH but also provide chemical stability and can influence protein folding; surfactants not only prevent aggregation but also maintain solubility and can protect against denaturation; sugars not only stabilize structure but also provide cryoprotection and prevent crystallization. This multi-functionality reduces the total number of excipients needed and simplifies formulation development.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The formulation ensures high recovery of non-aggregated and non-degraded anti-PCSK9 antibodies, retains biological potency, and maintains suitable viscosity, even under varying storage conditions, enhancing stability and convenience of administration.
Implementation Method 1
The stability of an antibody in liquid formulation depends not only on the kinds of excipients used in the formulation, but also on the amounts and proportions of the excipients relative to one another
Implementation Method 2
therapeutic antibodies in liquid solution are prone to degradation, aggregation or undesired chemical modifications unless the solution is formulated properly
Implementation Method 3
a stabilizer... optimized to maintain stability and bioavailability
Implementation Method 4
a viscosity reducer... to ensure the antibody remains effective and stable
Data Source
AI summary
The present invention provides pharmaceutical formulations comprising a human antibody that specifically binds to human proprotein convertase subtilisin/kexin type 9 (PCSK9). The formulations may contain, in addition to an anti-PCSK9 antibody, at least one amino acid, at least one sugar, or at least one non-ionic surfactant. The pharmaceutical formulations of the present invention exhibit a substantial degree of antibody stability after storage for several months.